A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation
BackgroundRituximab (RTX) represents an established therapeutic option for myasthenia gravis refractory to conventional immunotherapy. However, its heterogeneous efficacy across populations creates a challenge in clinical application, necessitating the…